Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib
DOI:
https://doi.org/10.19156/abtpn.2018.0044Keywords:
Metastatic breast cancer, HER2, Lapatinib, Trastuzumab resistance, Pertuzumab resistanceAbstract
Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, progressing after treatment with trastuzumab, pertuzumab and T-DM1, who obtained a regression of hepatic metastases after treatment with lapatinib-capecitabine (Oncology).